Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a situation where a proven instance is being copied into additional places with demand already visible. The transcript discusses various products, but the key is whether there is a specific, identifiable piece of the company that has been proven and is being replicated now. Looking at the transcript, there is discussion of biosimilars. Murdo Gordon says: "we're pleased to have launched our first commercial biosimilar products in Europe. We're excited to have launched KANJINTI, a biosimilar version of Herceptin, and earlier this month we launched AMGEVITA, Amgen's biosimilar to Humira, across a number of European countries. We have eight additional biosimilar programs in development and we expect this business to be an important growth driver for years to come." This indicates they have launched biosimilars in Europe, and they have additional programs in development. But are they currently standing up more instances? They have eight additional programs in development, but that is not necessarily "physically being stood up now" - they are in development, not yet launched. Also, the demand at destination? They mention "we expect this business to be an important growth driver" but that is future expectation, not demand already identified. Also, the proven instance? They have launched KANJINTI and AMGEVITA, but it's early days. They say "early days still" and "so far so good." But is that a proven instance that works? They have sales, but it's not clear that it's a proven instance with significant results. Also, the replication is not physically being stood up now; they have eight additional programs in development, but that is not the same as standing up copies of the same thing. They are different biosimilars, not copies of the same product. So that doesn't fit. Another possibility: Aimovig launch. They have launched Aimovig and it's a strong launch. But are they replicating it? No, it's a single product launch. They are expanding into markets? They mention international expansion, but that is not a specific replication of a proven unit. What about Prolia? They have strong growth, but that is within existing footprint.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.